Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and Nonalcoholic Fatty Liver Disease

NCT06564584 is registered in ClinicalTrials.gov with OrsoBio, Inc as lead sponsor.

NCT NCT06564584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06564584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and Nonalcoholic Fatty Liver Disease
Lead sponsor
OrsoBio, Inc
Phase
Phase 2
Overall status
Recruiting
Start date
August 12, 2024
Completion date
September 30, 2025
Enrollment
30 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hypertriglyceridemia, nonalcoholic fatty liver disease